Bjerre

About Steen Bjerre

This author has not yet filled in any details.
So far Steen Bjerre has created 222 blog entries.

Pharming celebrates hae day :-)

2019-05-20T18:02:07+00:00May 16, 2019|HAEi News|

On 16 May each year, HAE patient organisations from around the world, led by the HAEi, the international umbrella organisation for the world’s HAE patient groups, come together to support awareness of HAE. hae day :-) aims to raise global awareness to ensure each and every patient receives faster diagnosis and the care they need [...]

BioCryst reports significant progress

2019-05-15T11:32:31+00:00May 8, 2019|HAEi News|

“In a year with many milestones across our multiple advancing programs of oral medicines for rare diseases, BioCryst Pharmaceuticals, Inc. has achieved significant progress in the first quarter and we look forward to reporting data from our APeX-2 trial in the second quarter and filing a new drug application by the end of the year,” [...]

“Global Perspectives” #1/2019 out now

2019-05-15T10:36:49+00:00April 7, 2019|HAEi News|

Dear HAE friends, Welcome to the first 2019 issue of the HAEi magazine Global Perspectives. This time you will, among many other items, find information on: HAEi fulfills the General Assembly mandate HAEi now has a Chief Regional Patient Advocate 44 HAE pilgrims to walk the Camino HAEi brings hope to India Inspiring stories from HAEi [...]

On the way towards a once-daily oral HAE therapy

2019-05-07T12:47:12+00:00March 4, 2019|HAEi News|

In its financial results for the full year ended 31 December 2018 the BioCryst Pharmaceuticals, Inc. President and CEO Jon Stonehouse said: “In a year with many transformative milestones for BioCryst, it has been exciting to see so much progress already in the first two months of the year. The strong Phase 2 clinical data from our [...]

Potentially ideal profile for oral on-demand treatment of HAE

2019-05-07T12:49:00+00:00February 26, 2019|HAEi News|

In conjunction with the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2019 in San Francisco, CA. KalVista Pharmaceuticals, Inc. CEO Andrew Crockett said: “We are pleased to provide additional data on KVD900, showcasing a potentially ideal profile for oral on-demand treatment of HAE. Both formulations tested were rapidly and highly absorbed, driving a [...]

Results Confirm Rapid Onset of Action, Sustained Activity and Robust Dose Response

2019-05-07T12:50:03+00:00February 24, 2019|HAEi News|

BioCryst Pharmaceuticals, Inc. reports additional topline data from the Phase 2 ZENITH-1 trial, including new data from the 250 mg and 500 mg dose cohorts. Data from the now complete trial confirm previously reported results showing a single dose of oral 750 mg BCX7353 was well-tolerated and superior to placebo (p<0.05) against the majority of [...]

Attune Advances Medication for Treatment of HAE

2019-02-20T11:20:23+00:00January 25, 2019|East & Southeast Asia, HAEi News|

Attune Pharmaceuticals, Inc. announces the completion of a $23 million Series B financing with the proceeds to be used to advance a pipeline including the ongoing clinical development of ATN-249, a novel orally-administered plasma kallikrein inhibitor for the treatment of HAE. Andrew McDonald, Ph.D., CEO of Attune, said, “This financing brings together a syndicate of [...]

Serving an important role in the management of HAE

2019-02-22T11:33:56+00:00January 23, 2019|HAEi News|

Following the presentation of two abstracts at the Western Society of Allergy, Asthma and Immunology (WSAAI) in Maui, Hawaii, USA, the Pharming Group N.V. COO Bruno Giannetti (MD, PhD) said: “This real-world evidence demonstrates that Ruconest continues to serve an important role in the management of HAE despite the availability of other therapeutic options.” The presentations are: [...]

Positive Phase 1 Results for Oral Plasma Kallikrein Inhibitor

2019-02-18T09:47:12+00:00January 22, 2019|HAEi News|

Attune Pharmaceuticals announces the positive results from the first in human studies evaluating ATN-249, a novel orally administered plasma kallikrein inhibitor for the treatment of HAE. The data were presented by Ira Kalfus, M.D., chief medical officer of Attune, as a poster presentation at the Western Society of Allergy, Asthma and Immunology (WSAAI) 2019 Annual [...]